Diversified healthcare company CVS Health (NYSE:CVS) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 8.4% year on year to $98.92 billion. Its non-GAAP profit of $1.81 per share was 23.9% above analysts’ consensus estimates.
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 11.9%. This performance is a stark contrast from the S&P 500’s 4.3% gain.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at CVS Health (NYSE:CVS) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Oscar Health (NYSE:OSCR) and the best and worst performers in the health insurance providers industry.
The case stems from a whistleblower lawsuit filed by a former Aetna actuary who alleged CVS Caremark manipulated drug pricing to inflate Medicare claims while underpaying pharmacies.
